Monte Rosa Therapeutics (GLUE)
NASDAQ:GLUE
Total Valuation
Monte Rosa Therapeutics has a market cap or net worth of $1.35B. The enterprise value is $1.01B.
Market Cap$1.35B
Enterprise Value$1.01B
Share Statistics
Monte Rosa Therapeutics has 80,015,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding80,015,670
Owned by Insiders11.02%
Owned by Institutions49.26%
Financial Efficiency
Monte Rosa Therapeutics’s return on equity (ROE) is -0.17 and return on invested capital (ROIC) is -13.56%.
Return on Equity (ROE)-0.17
Return on Assets (ROA)-0.09
Return on Invested Capital (ROIC)-13.56%
Return on Capital Employed (ROCE)-0.14
Revenue Per Employee870.93K
Profits Per Employee-272.01K
Employee Count142
Asset Turnover0.28
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Monte Rosa Therapeutics is ―. Monte Rosa Therapeutics’s PEG ratio is 0.64.
PE Ratio―
PS Ratio10.53
PB Ratio5.59
Price to Fair Value5.59
Price to FCF-47.37
Price to Operating Cash Flow-48.67
PEG Ratio0.64
Income Statement
In the last 12 months, Monte Rosa Therapeutics had revenue of 123.67M and earned -38.63M in profits. Earnings per share was -0.46.
Revenue123.67M
Gross Profit115.32M
Operating Income-54.21M
Pretax Income-39.72M
Net Income-38.63M
EBITDA-45.85M
Earnings Per Share (EPS)-0.46
Cash Flow
In the last 12 months, operating cash flow was -22.80M and capital expenditures -4.70M, giving a free cash flow of -27.50M billion.
Operating Cash Flow-22.80M
Free Cash Flow-27.50M
Free Cash Flow per Share-0.34
Dividends & Yields
Monte Rosa Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.74
52-Week Price Change331.89%
50-Day Moving Average18.16
200-Day Moving Average12.28
Relative Strength Index (RSI)51.07
Average Volume (3m)1.23M
Important Dates
Monte Rosa Therapeutics upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateMar 17, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Monte Rosa Therapeutics as a current ratio of 6.12, with Debt / Equity ratio of 16.82%
Current Ratio6.12
Quick Ratio6.12
Debt to Market Cap0.03
Net Debt to EBITDA1.98
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Monte Rosa Therapeutics has paid -1.10M in taxes.
Income Tax-1.10M
Effective Tax Rate0.03
Enterprise Valuation
Monte Rosa Therapeutics EV to EBITDA ratio is -26.43, with an EV/FCF ratio of -44.07.
EV to Sales9.80
EV to EBITDA-26.43
EV to Free Cash Flow-44.07
EV to Operating Cash Flow-53.16
Balance Sheet
Monte Rosa Therapeutics has $377.10M in cash and marketable securities with $39.19M in debt, giving a net cash position of $337.91M billion.
Cash & Marketable Securities$377.10M
Total Debt$39.19M
Net Cash$337.91M
Net Cash Per Share$4.22
Tangible Book Value Per Share$2.81
Margins
Gross margin is 96.62%, with operating margin of -43.83%, and net profit margin of -31.23%.
Gross Margin96.62%
Operating Margin-43.83%
Pretax Margin-32.12%
Net Profit Margin-31.23%
EBITDA Margin-37.08%
EBIT Margin-43.83%
Analyst Forecast
The average price target for Monte Rosa Therapeutics is $32.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$32.60
Price Target Upside92.56% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast1112.27%
EPS Growth Forecast―